Reduced-intensity FOLFOXIRI in treating refractory metastatic colorectal cancer

Hung Ming Chen, Jen Kou Lin, Wei Shone Chen, Jeng Kai Jiang, Shung Haur Yang, Yuan Tzu Lan, Chun Chi Lin, Hao Wei Teng*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Objectives: To report on the efficacy and safety of reduced-intensity FOLFOXIRI (RI-FOLFOXIRI) as salvage chemotherapy for patients with refractory metastatic colorectal cancer (mCRC). Methods: From October 2009 to March 2014, a total of 45 patients with refractory mCRC received RI-FOLFOXIRI as salvage chemotherapy. The initial dose of RI-FOLFOXIRI was 85% of the dose last used for each drug. All patients received a 2-hour infusion of folinate, followed by a bolus of 5-fluorouracil, and then 2400 to 3000 mg/m 2 for 46 hours; in addition, patients were either administered irinotecan on day 1 followed by oxaliplatin on day 3 (group A), oxaliplatin on day 1 followed by irinotecan on day 3 (group B), or irinotecan and oxaliplatin on day 1 (group C). Results: Seven patients (15.6%) showed a partial response, and 15 patients (33.3%) had stable disease. The median progression-free and overall survival durations were 3.9 and 7.6 months, respectively. Patients who had wild-type K-RAS showed a longer overall survival duration (8.5 vs. 7.0 mo; P=0.04) but no difference in progression-free survival durations (4.4 vs. 3.4 mo; P=0.20) compared with patients with mutant K-RAS. The most common adverse events were neutropenia (28.9%) and diarrhea (26.7%). Conclusions: RI-FOLFOXIRI as salvage chemotherapy is effective and enables management of patients with refractory mCRC.

Original languageEnglish
Pages (from-to)260-265
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number3
StatePublished - 1 May 2017


  • colorectal cancer
  • retrospective
  • salvage chemotherapy


Dive into the research topics of 'Reduced-intensity FOLFOXIRI in treating refractory metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this